RxDoctor Payments Data

Nathan Steinhafel

Pediatrics · Kittanning, PANPI 1437386927

Payments from drug & device makers

$3,971in general payments, 2019–2025

Across 218 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$1K
  • Alcon$720
  • Oyster Point Pharma, Inc.$447
  • Johnson & Johnson Vision Care, Inc.$343
  • Sun Pharmaceutical Industries Inc.$274
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$253
  • plus $842 from 10 others

What the payments were for

  • Food & beverage$3,971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,971 in reported general payments places this provider in the 95th percentile of 1,849 pediatrics providers in Pennsylvania.

See all pediatrics providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$40,155
Medicare patients
198
Services billed
474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost109$32,524
RestasisCyclosporine39$26,219
XiidraLifitegrast23$22,307
Cyclosporine43$17,144
MieboPerfluorohexyloctane/Pf11$10,458
SimbrinzaBrinzolamide/Brimonidine Tart41$8,372
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$7,313
VyzultaLatanoprostene Bunod24$5,904
Latanoprost249$3,669
TafluprostTafluprost/Pf25$3,411
CombiganBrimonidine Tartrate/Timolol14$3,028
Travoprost28$2,874
Brimonidine Tartrate42$2,435
Timolol Maleate56$717
Dorzolamide Hcl37$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$133$61,771162 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$1,091$38,66958 claims
AlconSimbrinza$720$8,37241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,849 pediatrics providers in Pennsylvania.

Other pediatrics in Kittanning

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →